2-cyclohexyl-1-methylpyrrolidine | 77972-89-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-cyclohexyl-1-methylpyrrolidine
• CAS: 77972-89-5
• 化学式: C₁₁H₂₁N
• 分子量: 167.294
• InChiKey: RNRUCSURVLXRGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-cyclohexyl-1-methylpyrrolidine 、 碘甲烷 生成 2-cyclohexyl-1,1-dimethylpyrrolidin-1-ium;iodide
  参考文献：
  名称：

  BLAKE K. W.; GILLIES I.; DENNEY R. C., J. CHEM. SOC. PERKIN TRANS., 1981, PART 1, NO 3, 700-702

  摘要：

  DOI：
• 作为产物：
  描述：

  在 C₃₃H₂₁IrN₃O₉S₃^(3-)*3Na⁽¹⁺⁾ 、 维生素 C 作用下， 以 aq. phosphate buffer 为溶剂， 反应 10.0h， 以95%的产率得到2-cyclohexyl-1-methylpyrrolidine
  参考文献：
  名称：

  通过在循环反应网络中结合光氧化还原和酶催化来对映选择性合成胺†

  摘要：

  首次证明了在水溶液中可见光驱动的亚胺还原为对映体富集的胺。在环状亚胺存在下，广泛使用的 [Ir(ppy) 3 ]（ppy = 2-苯基吡啶）光敏剂的新型水溶性变体的激发提供了高反应性的 α-氨基烷基，该自由基被氢原子转移拦截(HAT)从抗坏血酸或硫醇供体得到相应的胺。单胺氧化酶 (MAO-N-9) 选择性催化一种对映体氧化成相应的亚胺。在连续光照射下结合光氧化还原和生物催化过程，可以以优异的产率获得对映体富集的胺。据我们所知，这是首次证明同时发生的光氧化还原和酶催化可导致光驱动的胺不对称合成。

  DOI：

  10.1039/c8sc01561a

文献信息

• [EN] 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES<br/>[FR] COMPOSÉS 6-HÉTÉROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE UTILISÉS POUR LE TRAITEMENT DU CANCER ET DU DIABÈTE
  申请人：SPRINT BIOSCIENCE AB

  公开号：WO2017140843A1

  公开（公告）日：2017-08-24

  The invention provides novel 6-heterocyclyl-4-morpholin-4-yl-pyridine-2-one compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and A are as defined in the specification.

  该发明提供了公式（I）的新型6-杂环基-4-吗啡啉-4-基吡啶-2-酮化合物，包含该化合物的药物组合物，以及使用该化合物治疗癌症、糖尿病、炎症性疾病、神经退行性疾病、心血管疾病和病毒感染等疾病的方法；其中R1、R2、R3和A如规范中所定义。
• Synthesis of some substituted pyrrolidines from cyclopropyl carbonyl compounds
  作者：Keith W. Blake、Iain Gillies、Ronald C. Denney

  DOI：10.1039/p19810000700

  日期：——

  A series of alkyl and aryl cyclopropyl carbonyl compounds, when refluxed in N-methylformamide in the presence of magnesium chloride, gave variously substituted pyrrolidines.

  当在氯化镁存在下在N-甲基甲酰胺中回流时，一系列烷基和芳基环丙基羰基化合物得到不同取代的吡咯烷。
• Bicyclic derivatives as CETP inhibitors
  申请人：Kishida Masashi

  公开号：US20090227580A1

  公开（公告）日：2009-09-10

  The present invention relates to novel compounds of formula (I) or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.

  本发明涉及式(I)的新化合物或其药物组合物，其中所有变量在文本中定义。本发明进一步涉及使用本发明中的化合物治疗或延缓与CETP有关的疾病的进展。
• AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF
  申请人：Sugasawa Keizo

  公开号：US20100249088A1

  公开（公告）日：2010-09-30

  [Object] To provide a therapeutic and/or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action. [Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and/or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.

  [目的] 提供一种治疗和/或预防下尿道疾病引起的尿频、尿急和尿失禁的治疗剂和/或预防剂，包括膀胱过度活动、伴有下尿道疼痛的各种下尿道疾病，如间质性膀胱炎、慢性前列腺炎等，以及伴有疼痛的各种疾病，基于出色的trkA受体抑制作用。 [解决方案] 发现一种新型的唑类羧酰胺化合物，其中一种噻唑环或噁唑环通过羧酰胺键与苯环、吡啶环、吡嗪环、噻吩环、吡唑环或吡咯环结合，或其盐具有强效的trkA受体抑制活性，并发现它能够被用作治疗和/或预防剂，对于包括膀胱过度活动、伴有下尿道疼痛的各种下尿道疾病，如间质性膀胱炎、慢性前列腺炎等，以及伴有疼痛的各种疾病，具有出色的疗效和安全性，从而完成了本发明。
• BICYCLIC DERIVATIVES AS CETP INHIBITORS
  申请人：KISHIDA Masashi

  公开号：US20120225874A1

  公开（公告）日：2012-09-06

  The present invention relates to novel compounds of formula (I) or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.

  本发明涉及公式（I）的新化合物或其药物组成物，其中所有变量在文本中定义。本发明还涉及将本化合物用于治疗或延缓CETP参与的疾病的进展。